Biocon Biologics and Viatris Receive European Commission Approval for Abevmy (biosimilar, bevacizumab)

Shots:

• The EC has approved the Abevmy (100 & 400mg) for the treatment in metastatic colorectal carcinoma, metastatic breast cancer, NSCLC, glioblastoma, ovarian, cervical, and renal cancer as part of a specific regimen
• The approval follows CHMP’s positive opinion and is valid in all EU Member States as well as in the EEA countries Iceland, Liechtenstein, and Norway
• The approval will strengthen Biocon’s portfolio of biosimilars for cancer in the EU, which include biosimilar Trastuzumab and biosimilar Pegfilgrastim

Click here to­ read full press release/ article | Ref: Biocon | Image: Medicircle